Keywords: Huntington's disease; Parkinson's disease; Cognition; Review; 6-OHDA; MPTP; Behaviour; Phenotype; Cognitive tests; Basal ganglia; Corticostriatal; Dopamine;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: CI; cerebral ischemia; PD; Parkinson's disease; HD; Huntington's disease; SN; substancia nigra; DA; dopamine; GABA; gamma-aminobutyric acid; MSN; medium spiny neuron; CNS; central nervous system; NSC; neural stem cells; ES; embryonic stem; MSC; mesenchyma
Keywords: SNc; substantia nigra pars compacta; PD; Parkinson disease; NMS; nonmotor symptoms; MAO-B; monoamine oxidase-B; MPP+; 1-methyl-4-phenylpyridinium; MPTP; 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 6-OHDA; 6-hydroxy dopamine; GBA; glucocerebrosidase; STN
Keywords: Transplantation; Brain repair; Embryonic tissue; Drug-induced rotation; 6-OHDA; RT-PCR; Electrophysiology; Extracellular recordings; Firing rate; Beta-oscillatory activity;
Keywords: 6-OHDA; 6-hydroxy dopamine; EEG; electroencephalographic; GPe; external segments of the globus pallidus; GPi; internal segments of the globus pallidus; HCN; hyperpolarization-activated cation current; SNr; substantia nigra pars reticulata; STN; subthalami
Keywords: 6-OHDA; 6-hydroxy dopamine; AR-PD; autosomal recessive Parkinson's disease; BBB; blood-brain barrier; COX; cyclo-oxygenase; CR3/43; MHC Class II; DA; dopaminergic/dopamine; DAMPS; damage-associated molecular patterns; EBM11; anti CD-68; EGF; epidermal g
Keywords: Aβ; β-amyloid protein; AD; Alzheimer's disease; AP-1; Activator protein-1; AS; Atherosclerosis; CCl4; Carbon tetrachloride; CFA; Complete Freund's Adjuvant; CIA; Type II collagen-induced arthritis; CMM; Chinese Material Medica; Con A; Concanavalin A; CO
Keywords: PD; Parkinson's disease; AD; Alzheimer's disease; HD; Huntington's Disease; ALS; Amyotrophic Lateral Sclerosis; TAR DNA; binding protein TDP-43; TCA; tricarboxylic acid cycle; ROS; reactive oxygen species; MPTP; 1-methyl-4-phenyl-1,2,3,6-tetrahydrod
Keywords: Conditioned place preference; 6-OHDA; Parkinson; Reward
Keywords: GA; gallic acid; 6-OHDA; 6-hydroxydopamine; PD; Parkinson's disease; MFB; medial forebrain bundle; GPx; glutathione peroxidase; SNc; substantia nigra pars compacta; DA; dopamine; ROS; reactive oxygen species; LPO; lipid peroxidation; MDA; malondialdehyd
5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction
Keywords: L-DOPA; 5alpha-reductase; Dutasteride; Parkinson's disease; Dyskinesia; 6-OHDA; Neurosteroids; Dopamine;
Regulation of Pleiotrophin and Fyn in the striatum of rats undergoing L-DOPA-induced dyskinesia
Keywords: 6-OHDA; 6-hydroxydopamine; AIMs; abnormal involuntary movements; DA; dopamine; L-DOPA; L-3,4-dihidroxiphenyl-alanine; LID; L-DOPA induced dyskinesia; MSNs; medium spiny neurons; NMDA; N-methyl-d-aspartate; NMDAR; NMDA receptor; PD; Parkinson's Disease;
Silymarin prevents apoptosis through inhibiting the Bax/caspase-3 expression and suppresses toll like receptor-4 pathway in the SNc of 6-OHDA intoxicated rats
Keywords: Bax; Bcl-2-associated X protein; Bcl2; B-cell lymphoma 2; Caspase; cysteine-aspartic proteases; CNS; central nervous system; DA; dopaminergic; ECL; enhanced chemiluminescence; EDTA; ethylenediaminetetraacetic acid; ELISA; enzyme-linked immunosorbent ass
Neuroprotection against 6-OHDA toxicity in PC12 cells and mice through the Nrf2 pathway by a sesquiterpenoid from Tussilago farfara
Keywords: 6-OHDA; 6-hydroxydopamine; Act. D; actinomycin D; AD; Alzheimer's disease; APO; apomorphine; ARE; antioxidant response element; CHX; cycloheximide; DAT; dopamine transporter; DTT; dithiothreitol; ECN; 7β-(3-ethyl-cis-crotonoyloxy)-1α-(2-methylbutyryloxy
Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements
Keywords: 6-OHDA; 6-hydroxydopamine; AIMs; abnormal involuntary movements; ALO; axial, forelimb and orolingual; ANOVA; analysis of variance; Arc; activity-regulated cytoskeleton-associated protein; CDS; continuous dopaminergic stimulation; COMT; catechol-O-methyltr
6-Hydroxydopamine induces autophagic flux dysfunction by impairing transcription factor EB activation and lysosomal function in dopaminergic neurons and SH-SY5Y cells
Keywords: PD; Parkinson's disease; iPSC; induced pluripotent stem cells; 6-OHDA; 6-hydroxydopamine; DAT; dopamine transporter; ROS; reactive oxygen species; TUNEL; terminal deoxynucelotidyl transferase-mediated deoxyuridine triphosphate nick end labeling; CCK-8;
Behavioral and cellular dopamine D1 and D3 receptor-mediated synergy: Implications for L-DOPA-induced dyskinesia
Keywords: Parkinson's disease; L-DOPA-Induced dyskinesia; Abnormal involuntary movements; D1R-D3R interactions; DA; Dopamine; DOPAC; Dihydroxyphenylacetic acid; PD; Parkinson's disease; LID; L-DOPA-Induced Dyskinesia; D1R; Dopamine D1 Receptor; D2R; Dopamine D2 Rec
Suppression of autophagy in the brain of transgenic mice with overexpression of Ð53Т-mutant α-synuclein as an early event at synucleinopathy progression
Keywords: B6.Cg-Tg; transgenic mouse strain B6.Cg-Tg(Prnp-SNCA*A53T)23Mkle/J; CMA; chaperone-mediated autophagy; 6-OHDA; 6-hydroxy dopamine; LC3-II; light chain 3 of the microtubule-associated protein 1 conjugated with phosphatidylethanolamine; PD; Parkinson's di
Lateral but not Medial Hypothalamic AMPK Activation Occurs at the Hypoglycemic Nadir in Insulin-injected Male Rats: Impact of Caudal Dorsomedial Hindbrain Catecholamine Signaling
Keywords: 6-OHDA; 6-hydroxydopamine; A2; A2 noradrenergic; AMPK; adenosine 5â²-monophosphate-activated protein kinase; ARH; arcuate hypothalamic nucleus; CA; catecholamine; CV4; caudal fourth ventricle; EDTA; ethylenediaminetetraacetic acid; IIH; insulin-induced h
Targeting PERK signaling with the small molecule GSK2606414 prevents neurodegeneration in a model of Parkinson's disease
Keywords: PD; Parkinson's disease; SNpc; substantia nigra pars compacta; PrDs; prion-related disorders; UPR; unfolded protein response; ISR; integrated stress response; PERK; RNA-like ER kinase; ATF4; activating of transcription-4; ATF3; activating of transcription
Impaired glutamatergic projection from the motor cortex to the subthalamic nucleus in 6-hydroxydopamine-lesioned hemi-parkinsonian rats
Keywords: STN; subthalamic nucleus; PD; Parkinson's disease; HSV-GFP; herpes simplex virus-green fluorescent protein; HSV-1; herpes simplex virus type 1; VGluT1; vesicular glutamate transporter 1; M1; primary motor cortex; 6-OHDA; 6-hydroxydopamine; GPi; globus pal
Hypericum polyanthemum cyclohexane extract potentiates behavioral effects and neurodegeneration induced by nigral infusions of 6-hydroxydopamine in rats
Keywords: Hypericum polyanthemum; Parkinson's disease; 6-OHDA; Rat; Neurotoxic effect;
Novel indanone derivatives as MAO B/H3R dual-targeting ligands for treatment of Parkinson's disease
Keywords: Multi-targeting; Neurodegenerative diseases; Histamine H3 receptor antagonist; Monoamine oxidase inhibitor; Neurotransmitter dysregulation; Parkinson's disease; AChE; acetylcholinesterase; anal. calc.; elementary analysis calculated; BuChE; butyrylcholine
Neuroprotective effect of IDPU (1-(7-imino-3-propyl-2,3-dihydrothiazolo [4,5-d]pyrimidin-6(7H)-yl)urea) in 6-OHDA induced rodent model of hemiparkinson's disease
Keywords: 6-OHDA; Parkinson's disease; A2A receptor antagonist;
High fat diet feeding induced insulin resistance exacerbates 6-OHDA mediated neurotoxicity and behavioral abnormalities in rats
Keywords: Diabetes mellitus; Dopamine; High fat diet; Insulin resistance; Parkinson's disease; 6-OHDA;
Destruction of noradrenergic terminals increases dopamine concentration and reduces dopamine metabolism in the medial prefrontal cortex
Keywords: DA; dopamine; NE; noradrenaline; 6-OHDA; 6-hydroxydopamine; 6-OHDOPA; 2,4,5-trihydroxy-phenylalanine or 6-hydroxy-DOPA; PFC; prefrontal cortex; HPLC; high performance liquid chromatography; Noradrenaline; Dopamine; 6-OHDA; Prefrontal cortex; Rat;
Engineered exosomes: A new promise for the management of musculoskeletal diseases
Keywords: Engineered exosomes; Drug delivery; Musculoskeletal diseases; Regenerative medicine; Oncology; Immune system regulation; 3â²UTR; 3â²untranslated regions; 6-OHDA; 6-hydroxydopamine; APC; adenomatous polyposis coli; BRD7; bromo-domain-containing protein 7
Protective effects of γ-mangostin on 6-OHDA-induced toxicity in SH-SY5Y cells
Keywords: γ-mangostin; 6-OHDA; ROS; p-p38; Bax/Bcl-2 ratio; Caspase-3;
Novel oxindole derivatives prevent oxidative stress-induced cell death in mouse hippocampal HT22â¯cells
Keywords: ER stress; Ferroptosis; Oxidative stress; Oxindole; Oxytosis; Rasagiline; ATF6; activated transcription factor 6; ARE; antioxidant response element; DMEM; Dulbecco's modified Eagle's medium; ER; endoplasmic reticulum; Grp78; 78-kDa glucose-regulated prote
mGlu4 allosteric modulation for treating Parkinson's disease
Keywords: Parkinson's disease; Dyskinesia; Glutamate; Dopamine; mGlu4; 6-OHDA; 6-hydroxydopamine; ADX88178; 4-methyl-N-[5-methyl-4-(1H-pyrazol-4-yl)-1,3-thiazol-2-yl]pyrimidin-2-amine; AIM; abnormal involuntary movements; CODA-RET; complemented donor acceptor reson
Agomelatine's effect on circadian locomotor rhythm alteration and depressive-like behavior in 6-OHDA lesioned rats
Keywords: Parkinson's disease; Circadian rhythm; Locomotor activity; 6-OHDA; Agomelatine; Depression;
Intrastriatal Chromospheres' Transplant Reduces Nociception in Hemiparkinsonian Rats
Keywords: ANOVA; analysis of variance; AP; anterior-posterior; AUC; against time curves; PD; Parkinson's disease; SNc; substantia nigra; 6-OHDA; 6-hydroxydopamine; TH; tyrosine-hydroxylase; chromospheres; dopamine; Parkinson's disease; cell transplant;
Guanabenz promotes neuronal survival via enhancement of ATF4 and parkin expression in models of Parkinson disease
Keywords: 6-OHDA; 6-hydroxydopamine; ATF4; activating transcription factor 4; CPT; camptothecin; GA; guanabenz acetate; MPP+; 1-methyl-4-phenylpyridinium; PD; Parkinson's disease; SN; substantia nigra; TH; tyrosine hydroxylase; Parkinson's disease; ATF4; Parkin; Gu
The role of T cells in the pathogenesis of Parkinson's disease
Keywords: AD; Alzheimer's disease; ALS; amyotrophic lateral sclerosis; APC; antigen-presenting cell; AQP4; Aquaporin-4; BBB; blood-brain barrier; BCL6; B cell lymphoma 6; BCR; B cell receptor; BEC; brain endothelial cells; CCL20; C-C motif ligand 20; CCR2; C-C
Absence of regulator of G-protein signaling 4 does not protect against dopamine neuron dysfunction and injury in the mouse 6-hydroxydopamine lesion model of Parkinson's disease
Keywords: RGS4; Parkinson's disease; 6-OHDA; Mouse model; Histopathology; Behavior; Neuroprotection; Target validation; Substantia nigra;
Extracellular poly(ADP-ribose) is a neurotrophic signal that upregulates glial cell line-derived neurotrophic factor (GDNF) levels in vitro and in vivo
Keywords: PAR; GDNF; PARP-1; Cell death; Parkinson disease; ANOVA; one-way analysis of variance; BDNF; brain-derived neurotrophic factor; DMEM; Dulbecco's modified Eagle medium; ELISA; enzyme-linked immunosorbent assay; EDTA; ethylenediaminetetraacetic acid; EC-PAR
Treatment of Parkinson's disease in rats by Nrf2 transfection using MRI-guided focused ultrasound delivery of nanomicrobubbles
Keywords: Parkinson's disease (PD); Blood-brain-barrier (BBB); MRI-Guided focused ultrasound nanomicrobubble; Nuclear factor E2-related factor 2 (Nrf2); Reactive oxygen species (ROS); PD; Parkinson's disease; DBS; deep brain stimulation; BBB; blood-brain-barrier; M
Original articleContribution of the nitric oxide donor molsidomine and the antiparkinsonian drug l-DOPA to the modulation of the blood pressure in unilaterally 6-OHDA-lesioned rats
Keywords: BP; blood pressure; DA; dopamine; MFB; medial forebrain bundle; NO; nitric oxide; nNOS; neuronal nitric oxide synthase; 6-OHDA; 6-hydroxydopamine; OH; orthostatic hypotension; PD; Parkinson's disease; SNc; substantia nigra pars compacta; STR; striatum;
Neem (Azadirachta indica): An indian traditional panacea with modern molecular basis
Keywords: Cancer; Clinical trial; Human diseases; Molecular targets; Neem; Phytochemicals; 5-FU; 5-fluorouracil; 6-OHDA; 6-hydroxydopamine; AKT; AKT8 virus oncogene cellular homolog; ALT; alanine aminotransferase; AST; aspartate aminotransferase; Bcl-2; B-cell lymp
Dopamine D3 receptor-modulated neuroprotective effects of lisuride
Keywords: 6-hydroxydopamine; Dopamine; D3 receptor; Lisuride; Substantia nigra; 6-OHDA; 6-hydroxydopamine; DAergic; dopaminergic; E; embryonic day; l-DOPA; levodopa; PD; Parkinson's disease; SN; substantia nigra; TEM; transmission electron microscopy; TH; tyrosine
Signaling by growth/differentiation factor 5 through the bone morphogenetic protein receptor type IB protects neurons against kainic acid-induced neurodegeneration
Keywords: MPP+; 1-methyl-4-pyridinium; 6-OHDA; 6-hydroxydopamine; BMPRII; bone morphogenetic protein type II receptor; BMPRIB; bone morphogenetic protein type IB receptor; BMPRIB-CA; constitutively active BMPRIB; GAPDH; glyceraldehyde phosphate dehydrogenase; GDF-5
Phrenic and hypoglossal nerve activity during respiratory response to hypoxia in 6-OHDA unilateral model of Parkinson's disease
Keywords: A pre-I HG; amplitude of the pre-inspiratory hypoglossal activity; ANOVA; analysis of variance; 6-OHDA; 6-hydroxydopamine; Frequency; f; Ti; inspiratory time; Te; the expiratory time; Tc; respiratory cycle time; T pre-I HG; duration of pre-inspiratory hyp
Phenylalanine derivatives with modulating effects on human α1-glycine receptors and anticonvulsant activity in strychnine-induced seizure model in male adult rats
Keywords: ANOVA; analysis of variance; BAPTA; 1,2-bis(o-aminophenoxy)ethane-N,N,N9,N9-tetraacetic acid; DA; dopamine; DMSO; dimethylsulfoxide; MBS; Barth's solution; nAChR; nicotinic acetylcholine receptor; α1-GLYRs; α1-glycine receptor; ROS; radical oxygen spe
Research articleNeuroprotective effects of lentivirus-mediated cystathionine-beta-synthase overexpression against 6-OHDA-induced parkinson's disease rats
Keywords: PD; parkinson's disease; DA; dopaminergic; SN; substantia nigra; H2S; hydrogen sulfide; CBS; cystathionine-beta-synthas; 6-OHDA; 6-Hydroxydopamine; SOD; superoxide dismutase; GSH-Px; glutathione peroxidase; MDA; mlonic dialdehyde; α-SYN; α-synuclein; AO
Research PaperBDNF over-expression induces striatal serotonin fiber sprouting and increases the susceptibility to l-DOPA-induced dyskinesia in 6-OHDA-lesioned rats
Keywords: 6-OHDA; BDNF; Dyskinesia; SERT; LID; Parkinson's disease; Serotonin;
Daily consumption of methylene blue reduces attentional deficits and dopamine reduction in a 6-OHDA model of Parkinson's disease
Keywords: LID; l-dopa-induced dyskinesia; MB; methylene blue; NHS; normal horse serum; PB; phosphate buffer; PBS; phosphate-buffered saline; PD; Parkinson's disease; PFA; paraformaldehyde; SNc; substantia nigra; TH; tyrosine hydroxylase; VTA; ventral tegmental ar
Capillarisin augments anti-oxidative and anti-inflammatory responses by activating Nrf2/HO-1 signaling
Keywords: Anti-inflammatory; Antioxidant; Capillarisin; HO-1; JNK; Nrf2; 6-OHDA; 6-hydroxydopamine; ARE; antioxidant response element; COX2; cyclooxygenase2; DCF-DA; 2â²,7â²-dihydrofluorescein-diacetate; DMEM; Dulbecco's modified Eagle's medium; ERK; extracellula
Depressive-like neurochemical and behavioral markers of Parkinson's disease after 6-OHDA administered unilaterally to the rat medial forebrain bundle
Keywords: APO; apomorphine; DA; dopamine; HIP; hippocampus; 5-HT; serotonin; LC; locus coeruleus; MFB; medial forebrain bundle; NA; noradrenaline; 6-OHDA; 6-hydroxydopamine; PD; Parkinson's disease; PFC; prefrontal cortex; SN; substantia nigra; STR; striatum; Asy
Protective effects of a herbal extract combination of Bupleurum falcatum, Paeonia suffruticosa, and Angelica dahurica against MPTP-induced neurotoxicity via regulation of nuclear receptor-related 1 protein
Keywords: 6-OHDA; 6-hydroxydopamine; DAT; dopamine transporter; ERK; extracellular signal-regulated kinase; HPLC; high-performance liquid chromatography; MABH; herbal extract combination of Bupleuri Radix, Moutan Cortex Radicis and Angelica Dahuricae Radix; MPTP; 1
An altered blood-brain barrier contributes to brain iron accumulation and neuroinflammation in the 6-OHDA rat model of Parkinson's disease
Keywords: 6-OHDA; 6-hydroxydopamine; ANOVA; analysis of variance; BBB; blood-brain barrier; CD68; cluster of differentiation 68; FOV; field of view; GFAP; glial fibrillary acidic protein; IgG; immunoglobulin G; MRI; magnetic resonance imaging; NEX; number of exci